BioAtla and GATC Health announced a $40 million special purpose vehicle to fund advancement of ozuriftamab vedotin (Oz‑V), a CAB‑ROR2 antibody‑drug conjugate, into a registrational Phase 3 study for second‑line-plus oropharyngeal squamous cell carcinoma (OPSCC). The financing targets a planned registrational pathway and supports late‑stage operations. The SPV structure pools investor capital specifically for the Oz‑V program, allowing BioAtla to retain broader corporate flexibility while securing dedicated funds for the registrational study. The move underscores investor appetite for targeted ADC programs and for CAB (conditionally active biologic) platforms aimed at improving tumor selectivity.